Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

However, it is uncertain whether long-term treatment will result in higher bone mass.

In this study, the researchers present BMD and histomorphometric data on 5 years of GH treatment in GH-deficient men.

Who Took Part

The age groups tagged for this paper are adults, men only.

Thirty-eight adult men with childhood onset GH deficiency (20-35 years) were included in the study.

Twenty-six of these had multiple pituitary hormone deficiencies and were on stable conventional hormone replacement.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

BMD in various regions of the total body was calculated by computer software (head, trunk, arms, and legs).

Transiliac bone biopsies were obtained before and after 1 and 5 years of GH treatment.

What Was Measured

The subject headings attached to it are Bone Density, Hormone Replacement Therapy, Human Growth Hormone, Longitudinal Studies and Osteogenesis.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.